Tacedinaline
Product Specifications
UNSPSC Description
Tacedinaline (N-acetyldinaline) is an inhibitor of the histone deacetylase (HDAC) with IC50s of 0.9, 0.9, 1.2 μM for recombinant HDAC 1, 2 and 3 respectively.
Target Antigen
Apoptosis; HDAC
Type
Reference compound
Related Pathways
Apoptosis;Cell Cycle/DNA Damage;Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/CI-994.html
Purity
99.32
Solubility
DMSO : ≥ 50 mg/mL
Smiles
O=C(NC1=C(N)C=CC=C1)C2=CC=C(NC(C)=O)C=C2
Molecular Weight
269.30
References & Citations
[1]Moradei OM, et al. Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. J Med Chem. 2007 Nov 15;50(23):5543-6.|[2]Loprevite M, etal. In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines. Oncol Res. 2005;15(1):39-48.|[3]LoRusso PM, et al. Preclinical antitumor activity of CI-994. Invest New Drugs. 1996;14(4):349-56.|[4]Graziano MJ, et al. Immunotoxicity of the anticancer drug CI-994 in rats: effects on lymphoid tissue. Arch Toxicol. 1999 Apr-May;73(3):168-74.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-50934/Tacedinaline-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-50934/Tacedinaline-SDS-MedChemExpress.pdf
Clinical Information
Phase 3
CAS Number
112522-64-2
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS7063739 Inquire
Recombinant Burkholderia mallei Lipoprotein signal peptidase (lspA), partial
Ask
View Details 